Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force.

Bailey K, Cost C, Davis I, Glade-Bender J, Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein J, Reed D, Janeway K, Gorlick R, Lessnick S, DuBois S, Hingorani P.

F1000Res. 2019 Apr 15;8. pii: F1000 Faculty Rev-493. doi: 10.12688/f1000research.18139.1. eCollection 2019. Review.

2.

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.

Vormoor B, Curtin NJ.

Curr Opin Oncol. 2014 Jul;26(4):428-33. doi: 10.1097/CCO.0000000000000091. Review.

3.

A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group.

Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL; COG Ewing Sarcoma Biology Committee.

Front Oncol. 2013 Mar 20;3:57. doi: 10.3389/fonc.2013.00057. eCollection 2013.

4.

Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.

Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, Weir BA, Tsherniak A, Parasuraman S, Kim S, Alexe G, Stegmaier K.

Oncotarget. 2015 Oct 6;6(30):30178-93. doi: 10.18632/oncotarget.4903.

5.

Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.

van Maldegem AM, Bovée JV, Peterse EF, Hogendoorn PC, Gelderblom H.

Eur J Cancer. 2016 Jan;53:171-80. doi: 10.1016/j.ejca.2015.09.009. Epub 2016 Jan 5. Review.

PMID:
26765686
6.

New strategies in ewing sarcoma: lost in translation?

Arnaldez FI, Helman LJ.

Clin Cancer Res. 2014 Jun 15;20(12):3050-6. doi: 10.1158/1078-0432.CCR-13-0633. Epub 2014 Apr 22.

7.

Investigational therapies for Ewing sarcoma: a search without a clear finding.

Vornicova O, Bar-Sela G.

Expert Opin Investig Drugs. 2016 Jun;25(6):679-86. doi: 10.1517/13543784.2016.1168398. Epub 2016 Apr 7. Review.

PMID:
26988130
8.

Prospects and challenges for the development of new therapies for Ewing sarcoma.

Grohar PJ, Helman LJ.

Pharmacol Ther. 2013 Feb;137(2):216-24. doi: 10.1016/j.pharmthera.2012.10.004. Epub 2012 Oct 18. Review.

PMID:
23085431
9.

Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.

Potratz J, Tillmanns A, Berning P, Korsching E, Schaefer C, Lechtape B, Schleithoff C, Unland R, Schäfer KL, Müller-Tidow C, Jürgens H, Dirksen U.

Mol Oncol. 2016 May;10(5):677-92. doi: 10.1016/j.molonc.2015.12.009. Epub 2015 Dec 20.

10.

Cutaneous Ewing Sarcoma and Ewing Sarcoma of the Bone: Distinct Diseases.

Tavakkoli M, Mueller L.

Case Rep Oncol. 2018 Nov 12;11(3):729-734. doi: 10.1159/000492667. eCollection 2018 Sep-Dec.

11.

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.

DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Grier HE, Stegmaier K; Children's Oncology Group.

Pediatr Blood Cancer. 2009 Mar;52(3):324-7. doi: 10.1002/pbc.21822.

12.

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.

Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM, Demetri GD.

BMC Cancer. 2014 Nov 5;14:813. doi: 10.1186/1471-2407-14-813.

13.

Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.

Vo KT, Edwards JV, Epling CL, Sinclair E, Hawkins DS, Grier HE, Janeway KA, Barnette P, McIlvaine E, Krailo MD, Barkauskas DA, Matthay KK, Womer RB, Gorlick RG, Lessnick SL, Mackall CL, DuBois SG.

Clin Cancer Res. 2016 Jul 15;22(14):3643-50. doi: 10.1158/1078-0432.CCR-15-2516. Epub 2016 Feb 9.

14.

Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.

Lee HJ, Yoon C, Schmidt B, Park DJ, Zhang AY, Erkizan HV, Toretsky JA, Kirsch DG, Yoon SS.

Mol Cancer Ther. 2013 Nov;12(11):2591-600. doi: 10.1158/1535-7163.MCT-13-0338. Epub 2013 Aug 21.

15.

A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.

Guenther LM, Dharia NV, Ross L, Conway A, Robichaud AL, Catlett JL 2nd, Wechsler CS, Frank ES, Goodale A, Church AJ, Tseng YY, Guha R, McKnight CG, Janeway KA, Boehm JS, Mora J, Davis MI, Alexe G, Piccioni F, Stegmaier K.

Clin Cancer Res. 2019 Feb 15;25(4):1343-1357. doi: 10.1158/1078-0432.CCR-18-0372. Epub 2018 Nov 5.

PMID:
30397176
16.

Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, "undifferentiated small round cell tumors". A clinicopathologic, immunophenotypic and molecular analysis.

Machado I, Yoshida A, Morales MGN, Abrahão-Machado LF, Navarro S, Cruz J, Lavernia J, Parafioriti A, Picci P, Llombart-Bosch A.

Ann Diagn Pathol. 2018 Jun;34:1-12. doi: 10.1016/j.anndiagpath.2017.11.011. Epub 2017 Nov 29.

PMID:
29661713
17.

Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.

Lerman DM, Monument MJ, McIlvaine E, Liu XQ, Huang D, Monovich L, Beeler N, Gorlick RG, Marina NM, Womer RB, Bridge JA, Krailo MD, Randall RL, Lessnick SL; Children's Oncology Group Ewing Sarcoma Biology Committee.

Pediatr Blood Cancer. 2015 May;62(5):759-65. doi: 10.1002/pbc.25340. Epub 2014 Dec 2.

18.

Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee.

Meyer JS, Nadel HR, Marina N, Womer RB, Brown KL, Eary JF, Gorlick R, Grier HE, Randall RL, Lawlor ER, Lessnick SL, Schomberg PJ, Kailo MD.

Pediatr Blood Cancer. 2008 Aug;51(2):163-70. doi: 10.1002/pbc.21596.

PMID:
18454470
19.

A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.

Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM.

Eur J Cancer. 2012 Mar;48(4):579-85. doi: 10.1016/j.ejca.2011.09.027. Epub 2011 Nov 14.

PMID:
22088484
20.

Extraosseous Ewing sarcoma arising in a chronically lymphedematous limb.

McArdle DJT, Nott L, Harle R, McArdle JP.

J Vasc Surg Cases Innov Tech. 2018 Aug 17;4(3):210-215. doi: 10.1016/j.jvscit.2018.04.005. eCollection 2018 Sep.

Supplemental Content

Support Center